Skip to main content

Available Courses

A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure
  • Not accredited

Learning objectives

  • Recall guideline recommendations for the use of NT-proBNP in heart failure
  • Describe current practices in heart failure diagnosis and the impact on treatment outcomes
  • Develop an optimised approach to the timely diagnosis and management of heart failure
See more
Achieving Lipid Targets & Managing CV Risk: Reassessing our way with Statins
  • 1.00 EBAC

Learning objectives

  • Recall prevalence of patients who are statin uncontrolled/intolerant
  • Define the additive benefit of combination treatment compared with statin intensification
  • Name the non-statin LLTs offering proven CV protection
  • Identifying patients with indication for novel non-statin therapy
  • Initiate lipid-lowering strategies proven to lower future CV events
See more
Advanced Approaches to Combined Epicardial and Endocardial Strategies – From New Consensus to Practice
  • 1.00 EBAC

Learning objectives

  • Identify patient populations who may benefit from hybrid ablation
  • Summarise the existing rationale and evidence for hybrid ablation beyond atrial fibrillation
  • Understand how to integrate left atrial appendage exclusion in atrial ablation approaches
  • Examine key aspects of new consensus recommendations for hybrid ablation
See more
Advancing Patient Care in Hypertrophic Cardiomyopathy
  • 0.50 AMA PRA Credit

Learning objectives

  • Recall recent trial data for novel disease modifying therapy in HCM
  • Describe the evolving guideline directed approach to managing HCM
  • Develop an expert-led approach to implementing novel therapy in clinical practice
See more
An Expert Approach to Cardio-Renal Protection in CKD
  • 2.00 EBAC

Learning objectives

  • Recall clinical evidence and guidelines for the management of CKD patients without diabetes
  • Describe current gaps and barriers in evidence-based management for CKD without diabetes
  • Apply evidence based-management strategies to a case study
  • Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes
See more
Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches
  • 1.00 EBAC

Learning objectives

  • Understand the nature of amyloidosis and its effects on various organs, particularly the heart
  • Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
  • Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
  • Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
  • Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
  • Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
See more
Challenges in ATTR Amyloidosis: An Expert Debate
  • 1.00 EBAC

Learning objectives

  • Comprehend the unique challenges posed to cardiologists who encounter patients with ATTR amyloidosis
  • Initiate first steps in diagnosis of suspect individuals in accordance to latest guidance
  • Have enhanced awareness of the disease trajectory of patients with a mixed ATTR phenotype
  • Recall the limitations of existing therapies for ATTR-CM
  • List the advantages of emerging classes of agents being evaluated in ATTR-CM
See more
CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use
  • 2.00 EBAC

Learning objectives

  • Describe the burden of ASCVD in type 2 diabetes
  • Assign risk of future CV events to individuals with type 2 diabetes
  • Identify appropriate patients for GLP-1 RA therapy based on clinical trial outcome data to reduce ASCVD risk
  • Recall trial data of anti-diabetes medications that reduce ASCVD risk
  • Recall the pleiotropic effects of GLP-1 RAs and how these may impact CV outcomes
  • Describe how early adoption of anti-diabetes therapies with proven CV benefit can positively influence QOL
  • Adopt anti-diabetic therapies with proven ASCVD benefit
See more

Most Recent

View All
The Bigger Picture: An Expert Assessment on the True Impact of ATTR-CM
  • 1.00 EBAC

Learning objectives

  • Recall the most recent epidemiological data on ATTR-CM incidence and diagnostic trends
  • List red flags indicating the presence of ATTR amyloidosis
  • Identify patients who should undergo detailed diagnosis work-up or referral
  • List the advantages of emerging classes of agents being evaluated in ATTR-CM
See more
Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches
  • 1.00 EBAC

Learning objectives

  • Understand the nature of amyloidosis and its effects on various organs, particularly the heart
  • Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
  • Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
  • Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
  • Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
  • Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
See more